Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Observer-blind, Placebo-controlled, Four-way Cross-over Study to Study the Ability of Functional Magnetic Resonance Imaging (fMRI) of the Brain to Detect and Characterize the Effects of Single Doses of a Selective Serotonin Reuptake Inhibitor (Escitalopram [Lexapro(R)]), a Dopamine and Noradrenaline Reuptake Inhibitor and Psychostimulant (Methylphenidate [Ritalin(R)]), an Anti-glutamatergic Drug Candidate (mGluR5 Antagonist RO4917523), and Placebo in Healthy Subjects.

Next Previous
Trial Profile

Randomized, Observer-blind, Placebo-controlled, Four-way Cross-over Study to Study the Ability of Functional Magnetic Resonance Imaging (fMRI) of the Brain to Detect and Characterize the Effects of Single Doses of a Selective Serotonin Reuptake Inhibitor (Escitalopram [Lexapro(R)]), a Dopamine and Noradrenaline Reuptake Inhibitor and Psychostimulant (Methylphenidate [Ritalin(R)]), an Anti-glutamatergic Drug Candidate (mGluR5 Antagonist RO4917523), and Placebo in Healthy Subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Basimglurant (Primary) ; Escitalopram; Methylphenidate
  • Indications Attention-deficit hyperactivity disorder; Generalised anxiety disorder; Major depressive disorder; Narcolepsy
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Roche

Most Recent Events

  • 23 Jul 2011 NCT reports trial status as completed and actual end date as Jun 2011.
  • 18 Jan 2011 Actual patient number changed from 15 ato 25 as reported by ClinicalTrials.gov
  • 15 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top